AmgenAMGN
About: Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Employees: 28,000
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
24% more first-time investments, than exits
New positions opened: 292 | Existing positions closed: 235
1.79% more ownership
Funds ownership: 75.91% [Q3] → 77.7% (+1.79%) [Q4]
9% more call options, than puts
Call options by funds: $1.98B | Put options by funds: $1.82B
0% more funds holding
Funds holding: 2,789 [Q3] → 2,789 (+0) [Q4]
4% less repeat investments, than reductions
Existing positions increased: 1,062 | Existing positions reduced: 1,109
14% less capital invested
Capital invested by funds: $130B [Q3] → $111B (-$18.9B) [Q4]
46% less funds holding in top 10
Funds holding in top 10: 69 [Q3] → 37 (-32) [Q4]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
6 analyst ratings
UBS Colin Bristow 8% 1-year accuracy 1 / 12 met price target | 15%upside $319 | Neutral Maintained | 14 Apr 2025 |
Morgan Stanley Terence Flynn 24% 1-year accuracy 5 / 21 met price target | 19%upside $330 | Equal-Weight Maintained | 9 Apr 2025 |
B of A Securities Tim Anderson 53% 1-year accuracy 8 / 15 met price target | 6%upside $294 | Underperform Maintained | 5 Mar 2025 |
Piper Sandler David Amsellem 39% 1-year accuracy 13 / 33 met price target | 18%upside $329 | Overweight Maintained | 10 Feb 2025 |
Citigroup Geoff Meacham 27% 1-year accuracy 9 / 33 met price target | 6%upside $295 | Neutral Maintained | 28 Jan 2025 |
Financial journalist opinion
Based on 47 articles about AMGN published over the past 30 days
